Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …

The mesenchymal subtype of glioblastoma is thought to be determined by both cancer cell-
intrinsic alterations and extrinsic cellular interactions, but remains poorly understood. Here …

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …

Glioblastoma (GBM) is the most aggressive primary malignant brain cancer and urgently
requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy offers a …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …

Epigenetic remodeling is a molecular hallmark of gliomas, and it has been identified as a
key mediator of glioma progression. Epigenetic dysregulation contributes to gliomagenesis …

Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …